AllianceBernstein’s Summit Therapeutics SMMT Stock Holding History

AllianceBernstein’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$417K	Buy	22,004 +2,151	+11%	+$38.1K	﹤0.01%	2826
2026 Q1	$347K	Sell	19,853 -753	-4%	-$12.2K	﹤0.01%	2817
2025 Q4	$360K	Buy	20,606 +383	+2%	+$7.21K	﹤0.01%	2820
2025 Q3	$418K	Buy	20,223 +2,722	+16%	+$66K	﹤0.01%	2775
2025 Q2	$372K	Sell	17,501 -75,229	-81%	-$1.72M	﹤0.01%	2809
2025 Q1	$1.79M	Buy	92,730 +5,210	+6%	+$105K	﹤0.01%	1962
2024 Q4	$1.56M	Sell	87,520 -8,360	-9%	-$162K	﹤0.01%	2096
2024 Q3	$2.1M	Sell	95,880 -212,696	-69%	-$2.97M	﹤0.01%	1937
2024 Q2	$2.41M	Buy	308,576 +186,566	+153%	+$1.01M	﹤0.01%	1840
2024 Q1	$505K	Buy	122,010 +1,140	+0.9%	+$4.53K	﹤0.01%	2584
2023 Q4	$315K	Buy	120,870 +37,644	+45%	+$77.4K	﹤0.01%	2821
2023 Q3	$156K	Buy	83,226 +10,686	+15%	+$20.4K	﹤0.01%	3011
2023 Q2	$182K	Buy	+72,540	New	+$132K	﹤0.01%	3002

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AllianceBernstein's SMMT Position: Q2 2026 in Review

AllianceBernstein increased its Summit Therapeutics (SMMT) stake by 11% in Q2 2026, buying an estimated $38.1K and bringing the position to 22,004 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

AllianceBernstein first reported a position in SMMT in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.41M in Q2 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

AllianceBernstein held 22,004 shares of Summit Therapeutics worth $417K as of Q2 2026.
AllianceBernstein bought 2,151 Summit Therapeutics shares in Q2 2026, an estimated $38.1K.
Summit Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2826 holding.
AllianceBernstein first reported a position in Summit Therapeutics in Q2 2023 and has held it in 13 quarters since.
AllianceBernstein's Summit Therapeutics position peaked at $2.41M in Q2 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.